Jamia Hamdard Molecular Medicine JRF Vacancy | Jamia Recruits @ helpBIOTECH ~ helpBIOTECH

30 May 2017

Jamia Hamdard Molecular Medicine JRF Vacancy | Jamia Recruits @ helpBIOTECH

 helpBIOTECH CSIR Class Room Coaching 2017 June Batch



Post: JRF in Molecular Medicine 

Description:


Applications are invited from NET qualified candidates for the Ph.D. (PhD in Molecular Medicine) position in the Lab of Neuroscience & Drug Discovery, Department of Molecular Medicine, Jamia Hamdard (Hamdard University), New Delhi under the supervision of Dr. Surajit Ganguly. Seeking highly-motivated candidates committed to research in the area of molecular intervention strategies for Neuropsychiatric disorders. The research work will be multidisciplinary and collaborative in nature involving cell-line and animal-based research models. 

Eligibility: 

Candidates with CSIR/DBT/ICMR/Inspire or equivalent fellowships can only apply at this time. In addition, candidates having passed MSc in any branch of Life Sciences, M.Tech (Biotechnology) or any other related qualification with minimum of 55% marks or equivalent grade from any recognized Indian University or foreign University recognized by Association of Indian Universities (AIU) will be essential for admission. 

How To Apply:


Interested candidates who fulfill the eligibility criteria should apply online at Jamia Hamdard website: www.jamiahamdard.edu via following the link for “Online admission portal -2017”. 

For admission to PhD in Molecular Medicine, the candidates need to select PhD programmes under the School of Interdisciplinary Sciences and Technology as department/courses offered and choose Molecular Medicine as PhD subject.

Research Interest of Dr. Surajit Ganguly (surajit.ganguly@jamiahamdard.ac.in):

The overall goal of Dr Ganguly’s laboratory is to understand the role of metabolic acetate as epigenetic modifier in psychiatric disorder and CNS-specific tumors. The central question being asked is how various metabolic acetate donors can regulate epigenetic mechanisms to protect neuropsychiatric behavioral abnormalities. [Singh S et al (2016) Psychopharmacology (Berl) 233(7):1257-68; Choudhury A et al (2016) Behav Brain Res. 297:204-12]. 

0 comments:

Post a Comment

Don't Miss Updates | Subscribe helpBIOTECH Now